Business Wire

DAI-NIPPON-PRINTING

Share
DNP Accelerates Development of Photomask Manufacturing Process for 2nm Generation EUV Lithography

Dai Nippon Printing Co., Ltd. (DNP, TOKYO: 7912) has begun development of a photomask manufacturing for 2-nanometer (10-9 meter) generation logic semiconductors that support Extreme Ultra-Violet (EUV) lithography, the cutting-edge process for semiconductor manufacturing.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240319148117/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Image of EUV lithography with pellicle, a protective film for the photomask (Photo: Business Wire)

DNP will also act as a subcontractor and provide the newly developed technology to Tokyo-based Rapidus Corporation (Rapidus). Rapidus is participating in the Research and Development Project of the Enhanced Infrastructures for Post-5G Information and Communication Systems instigated by the New Energy and Industrial Technology Development Organization (NEDO).

[Background]

We have strengthened our ability to manufacture cutting-edge semiconductors with high productivity and quality. And in 2016, DNP was the world's first merchant photomask manufacturer to introduce the multi-beam mask writing tool (MBMW).
In 2023, we completed the development of a photomask manufacturing process for 3-nm generation EUV lithography, and commenced development of 2-nm generation technology. In response to the need for further miniaturization, we will begin full-scale development of a photomask manufacturing process for 2-nm generation EUV lithography, including the operation of second and third multi-electron beam mask lithography systems in FY 2024.
DNP plans to bring online its second and third MBMW mask lithography systems in FY 2024, accelerating the development of photomasks for 2-nm generation EUV lithography.
DNP will act as a subcontractor on Development of Advanced Semiconductor Manufacturing Technology (Commissioned) by Rapidus as part of the NEDO’s previously mentioned R&D project.

[Going Forward]
By FY 2025, DNP will complete the development of a manufacturing process for photomasks for 2-nm generation logic semiconductors that support EUV lithography. From FY 2026 onwards, we will push ahead with the establishment of production technology with a view to commencing mass production in FY 2027.
We have also begun development with an eye toward the 2-nm generation and beyond, and have signed an agreement with imec, a cutting-edge international research organization headquartered in Leuven, Belgium, to jointly develop next-generation EUV photomasks. DNP will continue to contribute to the growth of Japan's semiconductor industry by promoting development in collaboration with various partners within the framework of the international semiconductor industry.

More Details

About DNP

DNP was established in 1876, and has become a leading global company that leverages print-based solutions to engineer fresh business opportunities while protecting the environment and creating a more vibrant world for all. We capitalize on core competencies in microfabrication and precision coating technology to provide products for the display, electronic device, and optical film markets. We have also developed new products, such as vapor chamber and reflect array that offer next-generation communication solutions for more people-friendly information society.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240319148117/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Convatec Selects LTIMindtree for Strategic, AI-Powered SAP S/4HANA Transformation17.11.2025 09:30:00 CET | Press release

LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, has announced its selection as a strategic partner by Convatec, a leading global medical products and technologies company, for the implementation of SAP’s Digital Core – S/4HANA. As part of this engagement, LTIMindtree will support Convatec to implement SAP’s Digital Core – S/4HANA across its Convatec’s business operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251114580133/en/ Srini Rao, EVP and Chief Business Officer - Europe at LTIMindtree & Angie Goodwin, Chief Digital Information Officer at Convatec LTIMindtree will refresh Convatec’s SAP S/4HANA landscape, streamline business processes, and enable intelligent, AI-powered digital operations. The deployment will support Convatec’s goals for process standardisation and operational efficiency, forming the foundation for its next phase of strategic technology transf

GoWit Secures Strategic Investment Led by Nuwa Capital to Drive the Next Era of AI Retail Media in EMEA17.11.2025 09:09:00 CET | Press release

GoWit, the leading AdTech company in connected commerce and retail media, announced a strategic investment round led by Nuwa Capital, with participation from existing investors Formus Capital, APY Ventures, and DCP. The investment marks a milestone in GoWit’s mission to expand AI-powered commerce and retail media network and strengthen its leadership across EMEA. Accelerating AI-Powered Retail Media Across EMEA The new capital will fuel GoWit’s expansion and the development of next-generation AI tools to enhance ad performance, data intelligence, and monetization for retailers, brands, and agencies. GoWit’s technology is trusted by leading retailers and marketplaces, including Carrefour (Turkey), Union Coop (UAE), Raneen (Egypt), Toters Delivery (Lebanon), Mumzworld (UAE), and Heureka Group (Czech Republic). The company collaborates with ecosystem partners such as Goldbach (Switzerland), Spike Media (MENA), and Akinon (EMEA), building a connected retail media infrastructure. “We built

TRU Simulation’s Bell 525 Flight Simulator Receives FAA Interim Level C Qualification17.11.2025 09:00:00 CET | Press release

TRU Simulation + Training Inc., a Textron Inc. (NYSE:TXT) company, and an affiliate of Textron Aviation Inc. and Bell Textron Inc. today announced its Bell 525 Full Flight Simulator (FFS) located at the Bell Training Academy received Interim Level C qualification from the Federal Aviation Administration (FAA). Bell Textron Inc. has designed and will manufacture the Bell 525 helicopter. By achieving this milestone, pilots can earn more flight hours on the Bell 525 platform ahead of the rotorcraft’s expected FAA type certification. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117520706/en/ TRU Simulation’s Bell 525 Flight Simulator receives FAA Interim Level C qualification “The accuracy and realism of our Flight Simulation Devices play a crucial role in ensuring that pilots can effectively translate their training into real-world scenarios,” said Jerry Messaris, vice president and general manager, TRU Simulation. “This q

Polpharma Biologics Confirms U.S. Launch of Tyruko® (natalizumab), the First and Only Biosimilar for Multiple Sclerosis17.11.2025 08:52:00 CET | Press release

Polpharma Biologics, a biopharmaceutical company group focused on biosimilars development and manufacturing, today confirmed that Sandoz Tyruko® (natalizumab-sztn) is now available to patients in the United States. Tyruko® is the first and only FDA-approved biosimilar of natalizumab for the treatment of relapsing forms of multiple sclerosis (MS), and also for adult patients with moderately to severely active Crohn’s disease1. Tyruko® was developed by Polpharma Biologics and will be commercialized in the U.S. by its collaboration partner Sandoz, under an exclusive global license agreement. The launch marks a significant milestone in expanding access to high-quality, affordable treatment options for patients living with MS and Crohn’s disease in the United States. Emmanuelle Lepine, Chair of the Supervisory Board, Polpharma Biologics, commented: "The U.S. launch of Tyruko® marks a pivotal moment not only for Polpharma Biologics, but for patients across the United States. This milestone r

Lone Star Acquires Multi-Asset Real Estate Portfolio from St. James’s Place17.11.2025 08:01:00 CET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Real Estate Fund VII, L.P. has successfully completed the acquisition of a multi-asset real estate portfolio from St. James’s Place (SJP) and its Property Unit Trust and Life and Pensions Trust. SJP was advised by Invesco Real Estate, the global real estate investment manager, on the sale of the portfolio. The portfolio comprises 16 high-quality assets across the UK, including multi-let industrial (“MLI”), retail, and office properties. The largest component is the MLI portfolio, which consists of 10 separate property assets predominantly located in Greater London and South East England, and offering access to major transportation and industrial hubs — making them highly attractive for last-mile delivery and regional distribution. The office properties are all situated in London, while the retail assets consist of high-quality retail warehouses with strong tenant bases. Lone Star will implement an active asset

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye